Laura
Ekblad
Docent, Department of Clinical Medicine
MD, PhD
Specialist in Geriatrics and Family Medicine. Senior researcher, Turku Alzheimer Imaging Group, Turku PET Centre.
Contact
Areas of expertise
positron emission tomography
Alzheimer´s Disease
Insulin resistance
cognition
memory disorders
Research
My research focuses on early risk factors for memory disorders, especially Alzheimer´s disease. I am particularly interested in the associations between metabolic risk factors (insulin resistance, glucose intolerance, obesity) and cognitive decline.
Our lab uses multimodal neuroimaging (PET-imaging, MRI) combined with blood and CSF biomarkers and cognitive testing to explore the association between different risk factors and early cerebral changes of memory disorders.
I also run a project that examines possible cardiac side effects of anti-dementia agents in elderly memory clinic patients.
Publications
Associations of lifestyle factors with amyloid pathology in persons without dementia (2025)
Journal of Alzheimer's Disease
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients (2025)
Annals of Pharmacotherapy
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort (2025)
The Journal of Prevention of Alzheimer's Disease
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
APOE4 carriership status influences [11C]PiB white matter retention in cognitively healthy older adults (2025)
Neurobiology of Disease
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Metabolic dysfunction-associated steatotic liver disease as a predictor of cognitive performance: An 11-year population-based follow-up study (2025)
Digestive and Liver Disease
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Neuroinflammation in Parkinson’s disease : A study with [11C]PBR28 PET and cerebrospinal fluid markers (2025)
Parkinsonism and Related Disorders
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly (2024)
Alzheimer's Research and Therapy
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Midlife insulin resistance, APOE genotype, and change in late-life brain beta-amyloid accumulation : A 5-year follow-up [11C]PIB-PET study (2024)
Neurobiology of Disease
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
SV2A PET shows hippocampal synaptic loss in cognitively unimpaired <i>APOE</i> ε4/ε4 homozygotes (2024)
Alzheimer's and Dementia
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET (2024)
Neurobiology of Disease
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )